We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
Cap. Flow
-$10.3M
Cap. Flow %
-0.37%
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.7M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$13.3M
5
JNJ icon
Johnson & Johnson
JNJ
+$11.2M

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$23.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$12.8M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
AMGN icon
Amgen
AMGN
+$11.4M
5
AKRX
Akorn Inc
AKRX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Real Estate 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
126
Community Health Systems
CYH
$391M
$1.57M 0.06%
203,935
– –
WELL icon
127
Welltower
WELL
$170B
$1.5M 0.05%
21,400
– –
OVID icon
128
Ovid Therapeutics
OVID
$442M
$1.39M 0.05%
162,537
-373,287
-70% -$3.11M
HR icon
129
Healthcare Realty
HR
$7.46B
$1.37M 0.05%
46,000
– –
DOC icon
130
Healthpeak Properties
DOC
$15.2B
$1.27M 0.05%
45,500
– –
CHRS icon
131
Coherus Oncology
CHRS
$227M
$1.2M 0.04%
90,000
– –
ADVM
132
DELISTED
Adverum Biotechnologies
ADVM
$1.09M 0.04%
+30,008
New +$833K
XENE icon
133
Xenon Pharmaceuticals
XENE
$6.2B
$1.03M 0.04%
350,000
– –
AVXS
134
DELISTED
AveXis, Inc. Common Stock
AVXS
$967K 0.03%
10,000
– –
ORKA
135
Oruka Therapeutics
ORKA
$5.9B
$892K 0.03%
3,756
– –
BLCM
136
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$693K 0.02%
6,000
– –
XRN
137
Chiron Real Estate Inc
XRN
$516M
$659K 0.02%
14,680
– –
NVAX icon
138
Novavax
NVAX
$1.22B
$651K 0.02%
28,550
– –
CYTO
139
DELISTED
Altamira Therapeutics Ltd
CYTO
$635K 0.02%
10
– –
ADYX
140
DELISTED
Adynxx Inc
ADYX
$602K 0.02%
27,500
– –
QTNT
141
DELISTED
Quotient Limited Ordinary Shares
QTNT
$586K 0.02%
+2,972
New +$593K
ACIU icon
142
AC Immune
ACIU
$241M
$462K 0.02%
+40,919
New +$350K
XNCR icon
143
Xencor
XNCR
$1.59B
$458K 0.02%
20,000
– –
RMR icon
144
The RMR Group
RMR
$333M
$382K 0.01%
7,441
– –
EIGR
145
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$341K 0.01%
+1,034
New +$282K
CLDX icon
146
Celldex Therapeutics
CLDX
$3.02B
$303K 0.01%
7,053
– –
PTGX icon
147
Protagonist Therapeutics
PTGX
$8.92B
$138K ﹤0.01%
+7,822
New +$108K
QHC
148
DELISTED
Quorum Health Corporation
QHC
$123K ﹤0.01%
23,725
– –
LRMR icon
149
Larimar Therapeutics
LRMR
$397M
$47K ﹤0.01%
1,109
– –
BMY icon
150
Bristol-Myers Squibb
BMY
$132B
– –
-186,500
Closed -$10.4M
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
  • Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
  • Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
  • Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
  • Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
  • Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.